Liberal Acceptance Bias, Momentary Aberrant Salience, and Psychosis: An Experimental Experience Sampling Study.
aberrant salience
experimental experience sampling methodology
first-episode psychosis
prodrome
reasoning bias
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
18 06 2019
18 06 2019
Historique:
pubmed:
7
9
2018
medline:
1
7
2020
entrez:
7
9
2018
Statut:
ppublish
Résumé
Cognitive models of psychosis posit that reasoning biases are an important mechanism contributing to the formation of psychotic symptoms, in part through transforming anomalous experiences of aberrant salience into frank psychotic symptoms. This study aimed to investigate the interplay of liberal acceptance (LA) bias, which is a specific type of reasoning bias, and momentary aberrant salience in the development of paranoid and psychotic experiences in daily life in first-episode psychosis patients (FEP), at-risk mental state participants (ARMS), and controls. We used a novel experimental Experience Sampling Methodology (eESM) task for measuring LA bias (ie, decisions based on low probability estimates) and ESM measures of momentary aberrant salience and paranoid and psychotic experiences in 51 FEP, 46 ARMS, and 53 controls. We found evidence that LA bias was more likely to occur in FEP than in controls. Further, LA bias was associated with psychotic and paranoid experiences (all P < .007) and modified the association between momentary aberrant salience and psychotic experiences (χ2(df) = 7.4(2), P = .025) in ARMS, such that momentary salience was associated with more intense psychotic experiences in the presence of LA bias in ARMS, but not in FEP and controls. Our findings suggest that LA bias may be central for anomalous experiences such as momentary aberrant salience to increase intensity of psychotic experiences in at-risk individuals. Further, LA bias appears to be more likely to be present, but not directly linked to current intensity of psychotic experiences, in treated FEP. Novel eESM tasks open new avenues for targeting psychological processes under real-world conditions.
Identifiants
pubmed: 30189093
pii: 5090990
doi: 10.1093/schbul/sby116
pmc: PMC6581124
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-882Subventions
Organisme : Medical Research Council
ID : MR/J008915/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT087417
Pays : United Kingdom
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Schizophr Bull. 2006 Apr;32(2):327-31
pubmed: 16339971
Schizophr Bull. 2017 Jan;43(1):133-141
pubmed: 27220965
J Psychopharmacol. 2007 May;21(3):238-52
pubmed: 17591652
Br J Psychiatry. 2008 Jun;192(6):412-23
pubmed: 18515890
Schizophr Bull. 2016 May;42(3):712-22
pubmed: 26834027
J Abnorm Psychol. 2005 Aug;114(3):373-384
pubmed: 16117574
Schizophr Bull. 2010 Jan;36(1):151-6
pubmed: 18562343
Q J Exp Psychol A. 1988 Nov;40(4):801-12
pubmed: 3212213
Psychol Med. 2008 Jun;38(6):825-32
pubmed: 18205963
Br J Psychiatry. 2007 Oct;191:355-6
pubmed: 17906248
Psychol Med. 2009 Feb;39(2):199-209
pubmed: 18588739
J Biopharm Stat. 2001 Feb-May;11(1-2):9-21
pubmed: 11459446
Psychol Med. 2013 Jun;43(6):1133-49
pubmed: 22850401
Schizophr Bull. 2014 Jul;40(4):729-36
pubmed: 24860087
Arch Gen Psychiatry. 2001 Dec;58(12):1137-44
pubmed: 11735842
Annu Rev Clin Psychol. 2006;2:267-90
pubmed: 17716071
Acta Psychiatr Scand. 2011 Jan;123(1):28-35
pubmed: 20712824
Schizophr Bull. 2013 Jul;39(4):884-95
pubmed: 22258881
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Psychol Med. 2009 Nov;39(11):1821-9
pubmed: 19426569
Psychol Med. 2001 Feb;31(2):189-95
pubmed: 11232907
Psychol Med. 2005 May;35(5):733-41
pubmed: 15918350
Schizophr Bull. 2015 Mar;41(2):400-10
pubmed: 25053650
Br J Clin Psychol. 2005 Jun;44(Pt 2):193-207
pubmed: 16004654
Am J Psychiatry. 2003 Jan;160(1):13-23
pubmed: 12505794
Psychol Med. 2012 May;42(5):1003-12
pubmed: 22067414
Q J Exp Psychol (Hove). 2007 Aug;60(8):1041-62
pubmed: 17654390
Br J Psychiatry. 2016 Aug;209(2):107-13
pubmed: 26989099
Schizophr Res. 2019 Jan;203:80-87
pubmed: 28927863
Schizophr Res. 2005 Nov 1;79(1):59-68
pubmed: 16005191
Schizophr Bull. 2008 Sep;34(5):835-47
pubmed: 18591195
JAMA Psychiatry. 2013 Jan;70(1):107-20
pubmed: 23165428
Acta Psychiatr Scand. 2011 Jan;123(1):12-20
pubmed: 20712828
Curr Pharm Des. 2012;18(4):351-7
pubmed: 22239566
J Behav Ther Exp Psychiatry. 2017 Sep;56:106-112
pubmed: 27639287
J Abnorm Psychol. 2010 Feb;119(1):40-9
pubmed: 20141241
World Psychiatry. 2011 Oct;10(3):165-74
pubmed: 21991266
Br J Clin Psychol. 1999 Jun;38(2):113-54
pubmed: 10389596
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Biol Psychiatry. 2005 Jul 15;58(2):105-10
pubmed: 16038680
Schizophr Bull. 2016 Mar;42(2):264-9
pubmed: 26707864
Soc Psychiatry Psychiatr Epidemiol. 2002 Mar;37(3):97-104
pubmed: 11990012
Br J Clin Psychol. 2002 Nov;41(Pt 4):331-47
pubmed: 12437789
J Behav Ther Exp Psychiatry. 2017 Sep;56:12-20
pubmed: 27501907
Schizophr Bull. 2017 Mar 1;43(2):302-315
pubmed: 28204708
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Arch Gen Psychiatry. 2012 Mar;69(3):220-9
pubmed: 22393215
Schizophr Res. 1999 Aug 23;39(1):79-83
pubmed: 10480670
Soc Psychiatry Psychiatr Epidemiol. 2014 Aug;49(8):1179-89
pubmed: 25005465
Psychol Med. 2007 Oct;37(10):1377-91
pubmed: 17335638
J Behav Ther Exp Psychiatry. 2015 Sep;48:118-24
pubmed: 25817242